Investing in Turquoise Health

Growing up in Seoul, Korea, I used to love shopping at the night markets, where I’d go for the thrill of the chase of a good deal. None of the items were labeled with prices, and many items could be found in multiple stalls. You point to something and watch the shopkeeper squint her eyes and size you up for a second before naming an inflated price. You feign disgust and walk away but stop a few stalls down where they have the same item and ask for their price instead. Then you pit them against each other until you reach a satisfying number and make the purchase, maybe even picking up a few more if you can squeeze out a volume-based discount.

This is the same routine many patients contemplate when they’re told they need a specific medical procedure or drug, except the chase is anything but thrilling when it’s a matter of life or death, or at least a matter of wellbeing. You’ve likely seen stories about how the same healthcare service can vary by 3000% in price, sometimes between hospitals just a few miles from each other, and the excessive behaviors of hospitals suing patients for unpaid medical bills. 

This is an artifact of our legacy payor-provider contracting system, in which the contracted rate of a given service is rarely a reflection of true underlying cost, quality, or market dynamics. Rather, they are the manifestation of the contentious balance of power between healthcare providers and insurers – with patients stuck in the middle. And since the majority of patients choose care by prioritizing two seemingly simple criteria – whether the provider accepts their insurance and what the care will cost – these payor-provider contracts end up driving most healthcare navigation decisions. 

The contracts themselves are archaic and intricate. A given hospital system may have hundreds of different contracts across multiple payor entities; a given service might have over 50 different prices depending on payor product, site of care, and level of acuity. Value-based contracting only further complicates the issue. They also have numerous administrative policies embedded in them related to provider credentialing, claims submission, dispute handling, and payment terms. These high-stakes agreements are typically stored as monolithic PDF documents and fragile spreadsheets, which create significant inertia against dynamic renegotiations, repricing, and searchability of information.

As such, the CMS price transparency rules (e.g. the Hospital Price Transparency Rule and Transparency in Coverage Rule) that mandate public disclosure of contracted rates by hospitals and payors have created a massive headache for all involved due to both the technical challenges of assembling, cleaning, and systematically publishing the data and the resulting scrutiny over who is getting paid what, by whom, in what context. These rules, in addition to the No Surprises Act, have also been a forcing function for the industry to contemplate how it will systematize, scale, and ultimately industrialize the manner in which it conducts business, as it relates to reducing overall healthcare costs while improving customer experience.

Over the last few decades, the traditional markets in Seoul began to scale to larger mainstream shopping crowds through globally accessible e-commerce storefronts and distribution networks. Prices became set, transparent, and market-driven. For stores managing more than a few SKUs, it’s no longer tenable to set one-off pricing schemes or ignore competitive pricing dynamics for widely available commodity goods. Across the entire e-commerce industry, modern tech platforms have emerged to enable everything from product catalog management to bundles design, online distribution marketplaces to standardization of pricing and descriptive metadata. Retailers are now forced to differentiate based on the unique packaging of goods and tailored user experiences.

Turquoise Health is doing the same for healthcare pricing and contracting – provider organizations (health systems, medical groups, and digital health companies), payors (health plans, self-funded employers, and government entities), and even drug manufacturers are using the Turquoise platform to digitize their healthcare services catalogs and pricing, as well as assemble data-driven and modular contracts for individual services and bundles. It also automates the data collection, curation, and publication process to help payors and providers comply with their respective price transparency regulations. Ultimately, we believe that Turquoise is poised to become the system of record and B2B marketplace for payor-provider contracting that enables more intelligent, market-driven pricing practices and lays the path to transform care navigation and health experiences for patients.

We’re thrilled to continue backing Chris Severn and Adam Geitgey, the founders of Turquoise Health, by leading their Series A and supporting their efforts to create an atomic understanding of the economics of our healthcare markets at the thorny but critical intersection of payor, provider, and consumer.



The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see for additional important information.

Biology is eating the world

Sign up for our bio newsletter to get the a16z take on the future of biology and engineering.